எங்கள் குழு ஒவ்வொரு ஆண்டும் அமெரிக்கா, ஐரோப்பா மற்றும் ஆசியா முழுவதும் 1000 அறிவியல் சங்கங்களின் ஆதரவுடன் 3000+ உலகளாவிய மாநாட்டுத் தொடர் நிகழ்வுகளை ஏற்பாடு செய்து 700+ திறந்த அணுகல் இதழ்களை வெளியிடுகிறது, இதில் 50000 க்கும் மேற்பட்ட தலைசிறந்த ஆளுமைகள், புகழ்பெற்ற விஞ்ஞானிகள் ஆசிரியர் குழு உறுப்பினர்களாக உள்ளனர்.
அதிக வாசகர்கள் மற்றும் மேற்கோள்களைப் பெறும் திறந்த அணுகல் இதழ்கள்
700 இதழ்கள் மற்றும் 15,000,000 வாசகர்கள் ஒவ்வொரு பத்திரிகையும் 25,000+ வாசகர்களைப் பெறுகிறது
Kazuma Kobayashi, Fumihiko Fujita, Yusuke Inoue, Chika Sakimura, Sayaka Kuba, Taiiichiro Kosaka, Taiiichiro Kosaka, Kosho Yamanouchi, Kengo Kanetaka, Tamotsu Kuroki and Susumu Eguchi
Purpose: In Japan, elderly people account for more than 20% of the total population. The incidence of elderly patients with advanced/recurrent colorectal cancer (ARCC) has also been increasing. However, the optimal regimen for elderly patients, especially those older than 75 years of age (late-stage elderly), has not been established. This study aims to examine the optimal chemotherapeutic regimens for late-stage elderly patients, and focuses on combined chemotherapy with Bevacizumab (Bmab)+dihydropyrimidine (DPD) dehydrogenase inhibitory fluoropyrimidine (DIF).
Methods: Between January 1996 and October 2014, 30 late-stage elderly chemotherapy-naïve patients with ARCC (male/female=16/14; average age, 79.1 years) were retrospectively reviewed. The treatment regimens were: Bmab+DIF (n=11) and other regimens (n=19).
Results: The MST was 979 days, the median PFS was 350 days and the RR was 23.3%. The grade ≥3 AEs with each of the regimens were as follows: Bmab+DIF, 1.9%, other regimens, 14.4%. Although no significant differences were observed in the OS or PFS between Bmab+DIF and the other regimens, the rate of transition to a 2nd-line chemotherapy after disease progression following first-line treatment was higher with Bmab+DIF (54.6% [6/11]) than with the other regimens (38.9% [7/18]); however, this difference did not reach statistical significance.
Conclusions: It is possible to prolong survival through chemotherapy in both late-stage elderly patients and younger patients with ARCC. Although the only appropriate specific regimen was not confirmed, given that it was associated with a 100% disease control rate, good feasibility and smooth transition to 2nd-line chemotherapy, Bmab+DIF was suggested to be a candidate treatment for late-stage elderly patients with ARCC.